We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 6% below its sector, cheaper than its peers on earnings.
Sopharma AD, an international pharmaceutical company founded in Sofia, Bulgaria, in 1933, specializes in the research, development, manufacturing, and commercialization of a wide array of healthcare products. Its offerings span medicinal substances, finished drug formulations, veterinary vaccines, infusion solutions, and disposable plastic medical devices for both human and animal health, in addition to food supplements. The company's diverse product portfolio addresses numerous therapeutic categories, including cardiology, gastroenterology, pain management, cough and cold remedies, immunology and dermatology, respiratory conditions (like asthma), neurology and psychiatry, urology, and gynecology. Key products include Carsil for gastrointestinal issues, the analgesic Tempalgin, Tabex for smoking cessation, Tribestan to support sexual system functions, Broncholytin for coughs, the common pain reliever Analgin, Nivalin for peripheral nervous system disorders, and Methylprednisolon for severe allergies and critical medical situations. Beyond its core pharmaceutical business, Sopharma AD engages in a variety of other ventures. These include providing secondary packaging services for pharmaceuticals, leasing real estate, and operating in the retail sector for medicines and medical equipment. The company also handles the cultivation, collection, and trade of herbs and medicinal plants. Furthermore, it is involved in the trading, transport, and packaging of radioactive materials and nuclear equipment for medical applications, as well as household electronics and electrical equipment. Sopharma AD also offers market and public opinion research, provides franchising and know-how, and participates in various consulting and non-pharmaceutical activities, such as the production of veterinary vaccines and infusion solutions.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save SPH.WA and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.